Abstract 590P
Background
Approximately 30% of colorectal cancers arise from the rectum with surgical resection being the mainstay of treatment. For rectal cancers with high-risk pathological features or cases of LARC, preoperative NAT followed by total mesorectal excision +/- adjuvant therapy is recommended. However, this paradigm is associated with questionable survival benefits and high morbidity. Post-NAT and post-surgical risk stratification using ctDNA may help predict outcomes in LARC pts.
Methods
Plasma samples (n=90) from pts with LARC (N=30, median age: 67 years) were analyzed retrospectively. A tumor-informed assay (Signatera™) was used to quantify ctDNA pre-NAT, post-NAT, and post-surgery. Neoadjuvant rectal (NAR) score was calculated and compared to ctDNA status to predict recurrence risk and survival outcomes.
Results
At the pre-NAT time point, ctDNA detection rate was 90% (27/30). Pts who were ctDNA-positive either post-NAT (N=5) or post-surgery (N=3) had worse recurrence-free survival (RFS) (HR 8.4, 95%CI: 2.3-30, p<0.001 and HR 14, 95%CI: 3.1-66, p<0.001, respectively), when compared to ctDNA-negative pts. Similarly, pts with a high NAR score exhibited an inferior RFS when compared to those with a low-risk score (HR: 21, 95%CI: 2.6-2731, p=0.001). When utilized in combination with ctDNA status in the post-NAT setting, ctDNA-positive with an intermediate-high NAR score exhibited an inferior RFS compared to ctDNA-negative pts with a low NAR score (HR 33.5, 95%CI: 3.7-4419, p<0.001) with 100% recurrence rate. Likewise, post-surgery, ctDNA-positive pts with an intermediate-high NAR score exhibited an inferior RFS, with a recurrence rate of 37.5%, when compared to ctDNA-negative pts with a low NAR score, none of whom recurred (HR 75, 95%CI: 2.6-4916, p<0.001). In multivariate analysis, ctDNA status post-surgery (p=0.039) and pathological nodal status (p=0.033) were the most significant risk factors associated with recurrence.
Conclusions
Post-treatment ctDNA status either as a sole surrogate outcome measure or as an adjunct to the NAR score may predict NAT response, improve risk stratification and potentially improve outcomes in LARC pts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
G. Laliotis, E. Spickard: Financial Interests, Personal, Full or part-time Employment: Natera, Inc.; Financial Interests, Personal, Stocks/Shares: Natera, Inc. G.V. George: Financial Interests, Personal, Financially compensated role: Natera, Inc.. S. Sharma, A. Jurdi, H. Sethi: Financial Interests, Personal, Full or part-time Employment: Natera, Inc.; Financial Interests, Personal, Stocks or ownership: Natera, Inc. M.C. Liu: Financial Interests, Personal, Full or part-time Employment: Natera, Inc.; Financial Interests, Personal, Stocks/Shares: Natera, Inc.; Financial Interests, Institutional, Research Grant: Eisai, Exact Sciences, Genentech, Genomic Health, GRAIL, Menarini Silicon Biosystems, Merck, Novartis, Seattle Genetics, Tesaro; Financial Interests, Personal, Other: AstraZeneca, Genomic Health, Ionis; Financial Interests, Institutional, Advisory Board: AstraZeneca, Celgene, Roche/Genentech, Genomic Health, GRAIL, Ionis, Merck, Pfizer, Seattle Genetics, Syndax. G. Martinelli: Financial Interests, Institutional, Research Funding: Novartis, Bristol Myers Squibb, Amgen, AIRC, AIL, Genzyme, Celgene; Financial Interests, Personal, Speaker, Consultant, Advisor: Novartis, Bristol Myers Squibb, Amgen, AIRC, AIL, Genzyme, Celgene, Ariad Pharma, Roche; Financial Interests, Personal, Speaker’s Bureau: Novartis, Bristol Myers Squibb, Amgen, AIRC, AIL, Pfizer, Genzyme, Celgene Arida GSK; Financial Interests, Personal, Other: Novartis, Bristol Myers Squibb, Amgen, AIRC, AIL, Pfizer, Genzyme, Celgene Arida GSK. All other authors have declared no conflicts of interest.
Resources from the same session
528P - Progression risk after pregnancy in patients with glioma
Presenter: Annette Leibetseder
Session: Poster session 10
529P - Post-marketing surveillance data from patients ≥70 years of age with central nervous system malignancies treated with Tumor Treating Fields (TTFields) therapy between 2011–2022
Presenter: Wenyin Shi
Session: Poster session 10
530P - Ultra low bevacizumab (BEVULTRA-100) as a novel approach in symptomatic management of high grade glioma: Can minimal dose make a difference?
Presenter: P ANURADHA
Session: Poster session 10
531P - Tumor treating fields therapy for glioblastoma: Identifying needs and satisfaction of new and long-term users
Presenter: Eleni T. Batzianouli
Session: Poster session 10
532P - Nitric oxide is a target by a combo-drug for glioblastoma treatment
Presenter: Manish Tripathi
Session: Poster session 10
533P - Oligodendrogliomas: What is the impact after the introduction of the WHO molecular classification?
Presenter: Maria Angeles Vaz Salgado
Session: Poster session 10
534P - Glioblastoma treatment in patients older than 60 years: Hypofractionated radiotherapy and temozolomide versus conventional radiotherapy and temozolomide
Presenter: Teresa Pacheco
Session: Poster session 10
535P - Hypofractionated radiotherapy in fit elderly patients with glioblastoma: Relevant or detrimental?
Presenter: Carla Martín Abreu
Session: Poster session 10
536P - Safety and efficacy of silibinin in patients with brain metastases after stereotactic radiosurgery (SRS): The SUSTAIN trial
Presenter: Niccolò Bertini
Session: Poster session 10
537P - S100A9 serum levels are associated with survival prognosis in patients with brain metastases
Presenter: Ariane Steindl
Session: Poster session 10